Portage Biotech Inc (PRTG) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Portage Biotech Inc. reported a significant reduction in net loss to $1.4 million for the fiscal quarter ending September 30, 2024, compared to the previous year’s $5.2 million. This improvement is attributed to decreased R&D and operating expenses, as the company pauses its ADPORT-601 trial due to financial constraints. Portage is exploring strategic alternatives, including partnerships or mergers, to enhance shareholder value.
For further insights into PRTG stock, check out TipRanks’ Stock Analysis page.